

Special Issue

Significance of KRAS Gene Mutations in Colorectal Cancer (2nd Edition)

Message from the Guest Editors

Understanding biological and genetic factors is critical for therapeutic strategies and improved survival outcomes. One of these critical steps is understanding the mechanism and development of treatment targets for metastatic colorectal cancers with the KRAS mutation. Notably, KRAS mutations occur in many cancers with different mutation frequencies, but there is also considerable variation in mutation subtypes. Nonetheless, the future of KRAS-directed therapy is promising. The data require increasingly more effort to seek a better understanding and overcome what has, for a long time, been an undruggable target in oncology. The purpose of this Special Issue is to present advances regarding the heterogeneity of KRAS mutant tumors and multiple subtypes of KRAS mutant forms. Precise selection of patients for cancer-directed therapy will be necessary to ensure its efficacy. This Special Issue welcomes reviews, as well as original research articles, which should be submitted by the deadline of 31 March 2026.

Guest Editors

Dr. Grazia Palomba

Institute of Biomolecular Chemistry (ICB), Sassari, Italy

Dr. Maria Cristina Sini

Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche (CNR), 07100 Sassari, Italy

Deadline for manuscript submissions

31 March 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/230173

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)